A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GX-I7 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 25 Dec 2017
At a glance
- Drugs GX I7 (Primary) ; GX I7 (Primary)
- Indications Cervical intraepithelial neoplasia; Human papillomavirus infections; Leucopenia; Solid tumours
- Focus Adverse reactions
- Sponsors Genexine
- 25 Dec 2017 Status changed from active, no longer recruiting to completed, according to an I-Mab Biopharma media release.
- 18 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Oct 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2018.